Engineered virus targets deadly brain tumor in new trial
NCT ID NCT07076498
First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times
Summary
This early-phase study tests the safety of an engineered virus called M032 in 20 children and adults with diffuse midline glioma, a rare and aggressive brain tumor. Participants receive the virus directly into the tumor after completing standard radiation therapy. The goal is to see if this approach is safe and to monitor any side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can adding lenvatinib to standard care outsmart a tough brain cancer?
- Can a sharper beam of radiation shield the mind during brain tumor treatment?
- Can a tiny implant trap brain tumor cells and make radiation work better?
- Can a targeted pill slow brain tumor growth after surgery?
- Brain surgery gets a GPS: network maps may help remove tumors while preserving function